ATRI vs. ANIK, OSUR, CERS, UTMD, ICUI, EMBC, KIDS, SILK, FNA, and AORT
Should you be buying Atrion stock or one of its competitors? The main competitors of Atrion include Anika Therapeutics (ANIK), OraSure Technologies (OSUR), Cerus (CERS), Utah Medical Products (UTMD), ICU Medical (ICUI), Embecta (EMBC), OrthoPediatrics (KIDS), Silk Road Medical (SILK), Paragon 28 (FNA), and Artivion (AORT). These companies are all part of the "surgical & medical instruments" industry.
Atrion (NASDAQ:ATRI) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, community ranking, dividends and analyst recommendations.
Atrion has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Comparatively, Anika Therapeutics has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500.
Anika Therapeutics has a consensus price target of $29.50, indicating a potential upside of 19.14%. Given Anika Therapeutics' higher probable upside, analysts plainly believe Anika Therapeutics is more favorable than Atrion.
Atrion has a net margin of 10.60% compared to Anika Therapeutics' net margin of -45.39%. Atrion's return on equity of 7.75% beat Anika Therapeutics' return on equity.
66.2% of Atrion shares are held by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are held by institutional investors. 22.8% of Atrion shares are held by company insiders. Comparatively, 5.9% of Anika Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Atrion has higher revenue and earnings than Anika Therapeutics. Anika Therapeutics is trading at a lower price-to-earnings ratio than Atrion, indicating that it is currently the more affordable of the two stocks.
In the previous week, Atrion had 10 more articles in the media than Anika Therapeutics. MarketBeat recorded 12 mentions for Atrion and 2 mentions for Anika Therapeutics. Atrion's average media sentiment score of 0.97 beat Anika Therapeutics' score of 0.63 indicating that Atrion is being referred to more favorably in the media.
Anika Therapeutics received 171 more outperform votes than Atrion when rated by MarketBeat users. Likewise, 64.38% of users gave Anika Therapeutics an outperform vote while only 55.13% of users gave Atrion an outperform vote.
Summary
Atrion beats Anika Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Atrion News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATRI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
